1. Introduction {#s0005}
===============

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a new β-coronavirus responsible for the pandemic viral pneumonia known as COVID-19. The disease started in Wuhan, China in December 2019 and has rapidly spread throughout the world \[[@bb0005]\]. As of April 24, 2020, the overall outbreak had caused over 191,000 deaths and approximately 2,700,000 infections. SARS-CoV-2 shares genomic similarities with two human coronaviruses, SARS-CoV and MERS-CoV (about 80% and 50%, respectively), which have caused fatal infections in the past 20 years \[[@bb0010]\]. COVID-19 causes a wide spectrum of clinical manifestations, ranging from asymptomatic or paucisymptomatic forms (with cough, fever, myalgia, and malaise) to full-blown viral pneumonia, which can lead to acute respiratory distress syndrome (ARDS) \[[@bb0015],[@bb0020]\]. Currently, three phenotypes are observed in COVID-19 patients, indicating three stages of the infection's progression and extent: (i) "mild" (benign infection: 80%) in patients with minor and nonspecific symptoms who will not progress to a more severe disease; (ii) "moderate" (overt pneumonia with or without hypoxia and localized inflammation: 15%) in patients requiring hospitalization; and (iii) "severe" (systemic hyperinflammation and ARDS: 5%) in patients who require critical care management and at risk of fatal outcome (1-2%) \[[@bb0025],[@bb0030]\]. Despite multiple targeted and non-targeted interventions, no treatment has yet proven effective in treating COVID-19. Numerous clinical trials are ongoing.

As the pandemic progresses, the pathophysiology of COVID-19 is becoming clearer and the potential of multiple cytokine and/or anti-cytokine interventions is raised. Indeed, it has been reported that COVID-19 associates states of both immunodeficiency and hyperinflammation, with the latter being manifested by a cytokine storm.

In this paper, we summarize today's principal findings and attempt to establish a more definitive view of COVID-19 pathophysiology, focusing on one key question: "*How can antiviral immunity be reinforced and hyperinflammatory damages be avoided?"* In the second half of this paper, we will describe the early results of clinical investigations which have assessed targeted and non-targeted therapies.

In this review, we will not discuss antiviral strategies used to treat COVID-19, nor will we discuss how to manage the wide spectrum of SARS-CoV2 infection-related complications, such as thromboembolism, vasculitis (chilblains), acute kidney injury or neurologic involvements.

2. Overview of COVID-19 immunopathology {#s0010}
=======================================

2.1. Act 1: the virus entry {#s0015}
---------------------------

SARS-CoV-2 is a zoonotic β-coronavirus, which infects human airways and enters cells by binding its S (spike) protein envelope to the human angiotensin-converting enzyme 2 (hACE2) after S protein priming by host serine protease TMPRSS2 \[[@bb0035]\]. hACE2 is present in type II alveolar cells (representing about 80% of all hACE2-expressing cells), nasal mucosa, upper respiratory tract, endothelium, heart, kidney, and intestine cells \[[@bb0040]\]. It has been reported that patients with diabetes, hypertension, or patients treated with ibuprofen are at higher risk of contracting severe COVID-19 \[[@bb0045], [@bb0050], [@bb0055]\]. In these patients, because there is increased expression of hACE2 on lung epithelial cells, some authors have postulated a connection between these points \[[@bb0060]\]. Of note, another receptor, CD147, has been implicated in mediating host cell invasion by SARS-CoV-2 \[[@bb0065]\]. After binding to its receptor, the virus enters the cells through endocytosis, viral RNA is released into the cytosol, the virus exploits the cell machinery to replicate, and it is further excreted from the cell by exocytosis \[[@bb0070]\].

Lung injury directly induced by the virus remains poorly explained. Patients with high viral loads and long virus-shedding periods are at higher risk of severe COVID-19 \[[@bb0075]\]. The early onset of rapid viral replication may cause massive epithelial and endothelial cell apoptosis, vascular leakage, as well as pro-inflammatory mediator release \[[@bb0080]\]. Furthermore, hACE2 downregulation and shedding by viral S protein can cause dysfunction of the renin-angiotensin system and exacerbate inflammation and vascular permeability leading to acute lung injury \[[@bb0085],[@bb0090]\]. Finally, recent data have suggested that SARS-CoV-2 can directly infect T cells through receptor-dependent, S protein-mediated membrane fusion \[[@bb0095]\]. Nevertheless, T cells have a very low expression level of hACE2, suggesting either an alternative receptor or high S protein affinity for hACE2. T cell infection is abortive, meaning that SARS-CoV-2 cannot replicate within T cells but rather induces cell death \[[@bb0095]\]. In SARS-CoV infection, the modulation of TNF-α-converting enzyme (TACE or ADAM17) by the spike protein of SARS-CoV and hACE2 induces TNF-α production which may accentuate T cell apoptosis \[[@bb0100],[@bb0105]\]. In this vein, Xiong et al. reported upregulation of apoptosis, autophagy, and p53 pathways in PBMCs from COVID-19 patients, when compared to healthy controls \[[@bb0110]\].

2.2. Act 2: the innate immune response, first cytokine wave {#s0020}
-----------------------------------------------------------

Epidemiological studies have demonstrated an elevation of acute phase reactants in patients with COVID-19, including ESR, C-reactive protein (CRP), serum amyloid A, and ferritin, suggesting a rapid activation of the innate immune response \[[@bb0015],[@bb0115], [@bb0120], [@bb0125]\]. Accordingly, COVID-19 patients have high levels of circulating TNF-α, IL-1β, IL-1Ra, sIL-2Rα, IL-6, IL-10, IL-17, IL-18, IFN-γ, MCP-3, M-CSF, MIP-1a, G-CSF, IP-10 and MCP-1 \[[@bb0115],[@bb0130]\].

These results are suggestive of hypercytokinemia, which is a hallmark of COVID-19. Nevertheless, only the serum concentrations of certain of these cytokines make it possible to discriminate between mild, moderate, and severe cases (mainly IL-1 β, IL-1Ra, IL-6, IL-7, IL-10, IP-10, and TNF-α) \[[@bb0130]\]. In addition, the levels of these cytokines in mild/moderate cases are generally below levels observed in usual macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis (MAS/reHLH) or in severe cytokine release syndrome (CRS) \[[@bb0135],[@bb0140]\]. Thus, hypercytokinemia should be regarded as a general marker of SARS-CoV-2, while the term 'cytokine storm' should be kept for those situations of overly exuberant inflammation leading to critical conditions, such as ARDS, disseminated intravascular coagulation or multiple organ failure.

Within cells, RNA viruses are sensed by the innate immune system through three major classes of pattern recognition receptors (PRRs): toll-like receptors (i.e. TLR-3, -7, -8), RIG-I-like receptors (RLRs), and NOD-like receptors (NLRs) \[[@bb0145]\]. Among TLRs, only TLR-7 and -8 recognize single stranded viral genomic RNA. Nonetheless, other cytosolic sensors such as TLR-3 and RIG-I/MDA5 may detect the virus intermediates during intracellular replication, including double stranded RNA \[[@bb0150]\]. These recognitions then activate downstream signaling effectors, i.e. NF-ĸB and IRF3/7. NF-ĸB promotes the transcription of proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6, further triggering Th1 and Th17 inflammatory responses with subsequent secretion of IFN-γ and IL-17. IRF3/7 promote type-I IFN production, which in turn activates the JAK1/TYK2-STAT1/2 pathway. STAT1 and STAT2 form a complex with IRF9 that translocates into the nucleus where it initiates the transcription of hundreds of genes called IFN-stimulated genes (ISGs). An early and robust type-I IFN response is required as the very first line of defense to suppress viral replication and spread.

Early NLR engagement has also been postulated during the innate immune response against coronaviruses \[[@bb0080]\]. Evidence of NLRs directly recognizing viral RNA is scant \[[@bb0155]\], however, NLRs are more possibly involved in detecting intracellular homeostasis perturbations or danger signals, such as ROS production \[[@bb0160],[@bb0165]\]. Evidence of their involvement can be found in the observation of high levels of circulating IL-1β, IL1-Ra, and IL-18 \[[@bb0115],[@bb0130]\] and synergistic upregulation of *IL1* and *IL1RN* genes in the lung \[[@bb0170]\]. Indeed, some NLRs are able to assemble a multimolecular platform termed inflammasome (via recruiting the adaptor ASC, *apoptosis-associated speck-like protein containing a CARD*), which in turn activates the proinflammatory caspase-1. Caspase-1 cleaves and activates IL-1β and IL-18, and induces a hyperinflammatory form of cell death, termed pyroptosis, through the cleavage of the pore-forming gasdermin-D \[[@bb0160],[@bb0175]\]. IL-1 family cytokines include IL-1α, IL-1β, IL-18 and their bioavailability is regulated by soluble antagonists (IL-1Ra, IL-18BP) of either endogenous origin or resulting from therapeutic intervention \[[@bb0180],[@bb0185]\]. The most frequently studied inflammasome sensor, NLRP3, drives inflammation during SARS-CoV infection through several activating pathways \[[@bb0190], [@bb0195], [@bb0200], [@bb0205]\]. Given the similarities between SARS-CoV and SARS-CoV-2, comparable mechanisms likely intervene during the acute phase of COVID-19.

Of note, the cytosolic sensor RIG-I can also associate with ASC to form a non-canonical inflammasome inducing caspase-1 activation and subsequent IL1-β/IL-18 secretion and pyroptosis \[[@bb0210]\]. IL-1β secretion may itself contribute to hypercytokinemia since IL-1β further induces the expression of other proinflammatory cytokines such as TNF-α and IL-6.

Lastly, high levels of chemokines and their coupled receptors have been observed in COVID-19 patients \[[@bb0110],[@bb0115],[@bb0130]\]. Accordingly, analysis of the molecular signature within the BALFs of patients revealed a plethora of upregulated chemokine transcripts, including neutrophil-recruiting mediators (CXCL8, CXCL1, CXCL2, CXCL10, CCL2, CCL7) and other attractants of monocytes and immune cells (CXCL6, CXCL11, CCL2, CCL3, CCL4, CCL7, CCL8, CCL20) \[[@bb0170]\]. These results are consistent with pathological findings attesting to lung infiltration by monocytes, macrophages and neutrophils, in contrast with lower amounts of lymphocytes \[[@bb0215]\]. This hyperactivated chemotaxis may play a major role in developing a pulmonary-centric disease by driving accumulated immune cells into the lungs and restricting the immune response to this particular organ.

2.3. Act 3: the immunodeficient state {#s0025}
-------------------------------------

As stated above, type-I IFN is critical for protecting against viral infections, since it promotes intracellular RNA degradation and virus clearance, induces tissue repair, and triggers a prolonged adaptive immune response \[[@bb0220], [@bb0225], [@bb0230]\]. Type-I IFN is mainly produced by plasmacytoid dendritic cells (pDCs), which are less sensitive to productive viral infection and/or virus-mediated cytotoxicity and can produce other inflammatory cytokines, such as TNF-α and IL-6 or control T cell response \[[@bb0235],[@bb0240]\]. pDCs are circulating immune cells, which act as sentinels and are activated after physical contact with virally-infected cells and transfer of PAMPs to the TLR7 sensors in pDCs, part of a process termed *interferogenic synapse* \[[@bb0245]\]. This synapse enables robust type-I IFN production at the infected site, thereby possibly limiting viral replication and systemic deleterious response. Data derived from the SARS-CoV and MERS-CoV outbreaks have revealed that coronaviruses suppress type-I IFN response by interfering with PRRs or type-I IFN receptor-signaling pathways. For instance, SARS-CoV induces the degradation of RNA sensor adaptor molecules, MAVS and TRAF3/6, thus inhibiting IRF3 translocation into the nucleus. MERS-CoV employs additional strategies, such as repression of histone modifications. Both viruses inhibit JAK/STAT signaling by decreasing STAT1 phosphorylation.

Considering the 80% overlap between SARS-CoV and SARS-CoV-2, it has been speculated that the latter uses similar strategies to dampen innate immune response. Nevertheless, SARS-CoV2 appears to have lower pathogenicity than SARS-CoV (with about a 10%-fatality rate) suggesting a lesser IFN antagonism \[[@bb0250]\]. On the other hand, exceptional genetic defects or immunosenescence may account for a reduced type-I IFN response and greater severity of COVID-19. Accordingly increased age is associated with a poorer outcome \[[@bb0015],[@bb0030],[@bb0115],[@bb0255]\].

In mouse models of SARS-CoV and MERS-CoV infections, a delayed type-I IFN response may explain more severe disease, with compromised virus control and paradoxical hyperinflammation induced by type-I IFN itself \[[@bb0260]\]. This leads to an influx of neutrophils and monocytes-macrophages (the major sources of pro-inflammatory cytokines) and further apoptosis of T cells, epithelial and endothelial cells \[[@bb0260], [@bb0265], [@bb0270], [@bb0275]\]. These acute inflammatory mechanisms damage the pulmonary microvascular and alveolar barrier and cause vascular leakage and alveolar edema, converging to ARDS. Therefore, not only the strength of the response but also its timing would appear to play a critical role in coronavirus infection ([Fig. 1](#f0005){ref-type="fig"} ).Fig. 1Kinetics and intensity of the antiviral response are decisive in COVID-19 outcome. In mild to moderate COVID-19, the early antiviral response, mostly type-I interferon (IFN), allows the rapid reduction of viral load and prevents T-cell depletion and hypercytokinemia. In severe COVID-19, delayed (solid green line) or low (dotted green line) antiviral response results in elevated lung cytokine/chemokine levels, impaired virus-specific T-cell responses, and acute clinical deterioration. Optimal times for therapeutic interventions are proposed. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 1

*In vitro*, SARS-COV-2 displays a greater sensitivity to type-I IFN than SARS-COV\[[@bb0280]\]. Furthermore, SARS-CoV-2 does not impair STAT1 phosphorylation. Interestingly, mild/moderate infection by SARS-CoV-2 is associated with a potent type-I IFN response, characterized by the robust expression of ISGs in patients' BALFs \[[@bb0170]\]. Moreover, preliminary results have revealed early IFN production in peripheral blood from patients with mild/moderate to severe forms during the first week of COVID-19 (\[[@bb9000]\]). In contrast, about 20% displayed no IFN production. Another study found the type-I IFN response to be high (between days 8-12) in mild-to-moderate patients while reduced in more severe patients who had a striking downregulation of IFN-stimulated genes \[[@bb0285]\]. These results are in line with previous conclusions and would indicate that the characteristics of type-I IFN response - both in terms of kinetics and intensity - could be linked to clinical outcome \[[@bb0260]\]. How exactly SARS-CoV-2 escapes type-I IFN in some patients remains to be elucidated.

Lymphopenia is one of the most prominent markers of COVID-19 and has been observed in over 80% of patients \[[@bb0115],[@bb0290],[@bb0295]\]. Analyses have shown that all subsets of lymphocytes were decreased, including CD4+ and CD8+ cytotoxic T cells \[[@bb0285],[@bb0300]\], natural killer (NK) cells, memory and regulatory T cells \[[@bb0305]\] along with B cells \[[@bb0310]\]. Lower lymphocyte counts are closely linked to severe disease \[[@bb0305],[@bb0310]\]. In addition to being quantitatively decreased, T cells exhibit elevated exhaustion levels and reduced functional diversity \[[@bb0300],[@bb0315]\]. T cell numbers are negatively correlated with serum IL-6, IL-10 and TNF-α and with higher levels of exhaustion markers, such as PD-1 or Tim-3 \[[@bb0285],[@bb0300],[@bb0320]\]. Patients with severe form of COVID-19 have less multifunctional and more non-functional CD4+ T cells, as well as fewer non-exhausted CD8+ T cells than patients with mild COVID-19 \[[@bb0315]\].

Several explanations are posited to explain this SARS-CoV-2-induced lymphopenia.

First, the virus can directly infect T cells but cannot replicate within the cells \[[@bb0095]\]. T cell infection may thus result in cell death by apoptosis, necrosis, or pyroptosis \[[@bb0095],[@bb0325],[@bb0330]\].

Second, a number of inhibitory cytokines are released by infected lung macrophages or epithelial cells (first wave of hypercytokinemia), including TNF-α which causes T cell apoptosis \[[@bb0105]\], IL-10 which is known to prevent T cell proliferation \[[@bb0335]\], and type-I IFN which regulates lymphocyte recirculation \[[@bb0340]\]. T cell exhaustion, characterizing severe COVID-19, may stem from increased PD-1 or Tim-3 expression, from elevated levels of inhibitory IL-10 \[[@bb0300]\] or from increased IL-6-induced expression of SOCS3 \[[@bb0345], [@bb0350], [@bb0355]\]. Interestingly, IL-2 and IL-7, the cytokines responsible for expansion and differentiation of various T cell subsets are increased in the sera of patients having either mild/moderate or severe forms of COVID-19 \[[@bb0115]\]. Nevertheless, these increased levels most likely represent attempts by the immune system to reverse lymphopenia and T cell exhaustion.

Lastly, lymphopenia has been thought to be the result of immune cells redistribution, with accumulation of lymphocytes in the lungs or lymphoid organs \[[@bb0360]\]. However, though pathological results are scarce and contradictory, it would seem that alveolar or interstitial tissues are not invaded by lymphocytes but rather by monocytes, macrophages and moderate numbers of multinucleated giant cells \[[@bb0215]\]. More intriguingly, autopsies have revealed that secondary lymphoid tissues had been destroyed with atrophied spleen and decreased lymphocyte numbers, accompanied by significant cell degeneration, focal hemorrhagic necrosis, plus macrophage proliferation and phagocytosis. Lymph nodes were atrophied and their number decreased, with signs of necrosis. Immunohistochemical staining demonstrated decreased rates of CD4+ and CD8+ T cells in the spleen and lymph nodes \[[@bb0305]\].

2.4. Act 4: the cytokine storm, a lethal second wave {#s0030}
----------------------------------------------------

Sudden and rapidly progressing clinical deterioration has been widely mentioned in late stages of COVID-19 (around 7-10 days). This often manifests as an unexpected aggravation of symptoms (fever, dyspnea) and is correlated with increased levels of acute phase reactants (ESR, CRP, ferritin), coagulopathy (elevated titers of d-dimers, disseminated intravascular coagulation), and cell lysis (CK, LDH) \[[@bb0015],[@bb0020],[@bb0055],[@bb0115],[@bb0295]\]. In the most severe patients, clinical and laboratory parameters correlated with increased levels of proinflammatory cytokines (IL-1β, IL-1Ra, IL-6, TNF-α, and sIL2-Rα), evocative of a cytokine storm \[[@bb0015],[@bb0365], [@bb0370], [@bb0375]\]. Interestingly, ARDS occurs in SARS-CoV patients despite a diminishing viral load, suggesting that exuberant host immune response may be responsible for this outcome rather than viral virulence. Such a cytokine profile is strongly reminiscent of both Cytokine Release Syndrome (CRS, seen in CAR T cell therapy) and hemophagocytic lymphohistiocytosis (HLH) \[[@bb0380],[@bb0385]\]. Numerous authors have paralleled the COVID-19 cytokine storm to either primary or reactive HLH (reHLH) because of its close resemblance, including high fever, cytopenia, hyperferritinemia, abnormal liver tests, coagulopathy, and pulmonary involvement (including ARDS), occurring in approximately 50% of patients with reHLH \[[@bb0365],[@bb0370],[@bb0390]\]. In adults, reHLH is most often triggered by viral infections and is observed in 3 - 4% of sepsis cases \[[@bb0395]\]. Herpesviridae (e.g. Epstein-Barr virus) and influenza are major triggers of such cytokine storms \[[@bb0385]\]. Systemic diseases, like systemic lupus erythematosus, or the autoinflammatory adult-onset Still's disease and its pediatric counterpart, can also be complicated by cytokine storm, known as the macrophage activation syndrome (identical to reHLH) \[[@bb0400], [@bb0405], [@bb0410]\]. In all these conditions, IL-1β, IL-18, IFN-γ, and IL-6 are key mediators of hyperinflammation.

Similar to what is observed in SARS-CoV-2 infection, the immunodeficiency linked to abnormal T cell number or function (genetically determined in primary HLH) appears to be the *primum mobile* of most cytokine storms \[[@bb0415], [@bb0420], [@bb0425], [@bb0430], [@bb0435]\]. Although an alternative pathway of primary hyperactivated innate immunity is possible, it is more likely that this cytokine storm occurs due to the combination of a defective (or delayed) first line of defense, followed by persistent hypercytokinemia (IL-6, IL-1β, and TNF-α), and dysfunctional T cell response (generally cytotoxicity). This results in an impaired clearance of apoptic cells or infected/activated macrophages, an increase in viral replication and dissemination, followed by an IL-18/IFN-γ feedforward loop activating macrophages, culminating in multiple cytokine release, hemophagocytosis, coagulopathy, and ARDS ([Fig. 2](#f0010){ref-type="fig"} ) \[[@bb0425],[@bb0440],[@bb0445]\]. Some of these mediators may further fuel this vicious cycle, including NK cell function impairment by IL-6 \[[@bb0355]\] or macrophage activation by the H-chain of ferritin \[[@bb0450], [@bb0455], [@bb0460]\]. Quite importantly, hemophagocytosis has been reported in lung tissues from patients who succumbed to SARS-CoV infection \[[@bb0465]\].Fig. 2The immunopathology of COVID-19.The entry of SARS-CoV-2 in epithelial/endothelial cells, via binding to ACE2 (and CD147), induces apoptotic and necroptotic pathways resulting in lung injury and release of numerous chemokines driving the recruitment of large amounts of immune cells within the lungs. Dendritic cells (DCs) and plasmacytoid DCs (pDCs, the main source of type-I interferon (IFN)), along with alveolar macrophages and neutrophils, promote the innate immune response by secreting alarmins and antiviral or proinflammatory cytokines, plus presenting the antigen to adaptive immune cells. SARS-CoV-2 may have evolved strategies to downregulate the type-I IFN response and induce T cell apoptosis. The recognition of molecular patterns (viral RNA, particles, or danger signals) by various Toll-like receptors (TLRs), NOD-like receptors (NLRs) or RIG-I like receptors (RLRs) activates the transcription and release of proinflammatory mediators, such as interleukin (IL)-1β, -6, -18, and tumor necrosis factor (TNF)-α. These mediators further skew naïve T-cells to Th1 or cytotoxic lymphocytes (CTLs or CD8+), which in turn secrete amounts of cytokines. A pro-inflammatory feedforward loop of cytokines on innate immune cells results in cytokine storm, coagulopathy, and acute respiratory distress syndrome (ARDS). COVID-19 cytokine storm may intertwine two mechanisms; one highly suggestive of macrophage activation syndrome (hemophagocytic lymphohistiocytosis, HLH) driven by IL-1β, and another pattern characterized by immune dysregulation driven by IL-6, which triggers immunoparalysis (decreased HLA-DR on CD14 monocytes) and global lymphopenia.Fig. 2

Thus, in COVID-19, the onset of ARDS may be the consequence of a HLH-like syndrome, after a first period of lung damage, mainly localized within the lungs due to a prior accumulation of large amounts of innate immune cells. Systemic features of HLH are lacking (such as extremely high titers of ferritinemia, organomegaly, and severe end-organ disease) but this is most probably the consequence of lymphoid organ immune cell depopulation of \[[@bb0215]\].

Analysing more precisely the immunopathology of SARS-CoV2-related ARDS, Giamarellos-Bourboulis *et al.* have come to the conclusion that two patterns of immune dysfunction exist in worsening COVID-19: (i) one pattern highly suggestive of macrophage activation syndrome (hyperferritinemia and elevated H score : 25% of patients), which is driven by IL-1β; and (ii) one pattern with immune dysregulation driven by IL-6 \[[@bb0355]\]. The latter was characterized by a combination of hypercytokinemia, immunoparalysis (as indicated by decreased HLA-DR molecules on CD14 monocytes), and global lymphopenia (including CD4+ and NK cells). Interestingly, IL-6 blockade with tocilizumab partially restored HLA-DR expression on CD14 monocytes and increased the circulating lymphocyte count.

A number of key points stand out in this overview of the immunopathology of SARS-CoV-2 infection:1)While the virus induces both impairment and hyperactivation of the immune system, these are sequential, and the latter seems to ensue from the former, at least partially;2)An early viral clearance by type-I IFN is a key to preventing further viral replication, T cell exhaustion, and subsequent cytokine storm;3)Therapies (when applicable) should be administered with the right timing; i.e. antivirals and immune boosters should be initiated promptly after symptom onset, whereas immunosuppressants should be administered at the very start of the cytokine storm ([Fig. 1](#f0005){ref-type="fig"});4)Given the great frequency of non-severe presentations, therapeutic interventions should be kept for selected patients (i.e. those with risk factors or worsening diseases). Nonetheless, except for advanced age, elevated body mass index, and comorbid conditions, there is still a lack of robust prognostic factors \[[@bb0015],[@bb0115],[@bb0120],[@bb0375]\].

Routine and non-routine markers can be monitored to help evaluate the risk of developing cytokine storm. However, at present, no cut-off value has yet been proposed for any of these markers. It would be of great benefit to analyze their trends in depth, along with daily clinical evaluation.

3. Cytokine-based interventions {#s0035}
===============================

3.1. Type-I interferon {#s0040}
----------------------

Since type-I IFN's key role in antiviral response and low or delayed IFN response has been associated with poor outcome, IFN-α and IFN-β have emerged as potentially effective drugs against SARS-CoV-2 \[[@bb0260],[@bb0470]\]. Evidence is mainly derived from experience with SARS-CoV and MERS-CoV infections \[[@bb0475]\]. *In vivo*, type-I is most often used in combination with other antiviral drugs, such as lopinavir/ritonavir \[[@bb0480], [@bb0485], [@bb0490], [@bb0495]\] or ribavirin \[[@bb0500], [@bb0505], [@bb0510]\]. *In vitro*, IFN-α and -β have very systematically demonstrated robust efficacy against coronaviruses, but proved disappointing when transposed to human diseases \[[@bb0475],[@bb0480],[@bb0500],[@bb0515]\]. Multiple biases in these trials have prevented drawing conclusions from them. These biases include: coronavirus escape strategies to type-I IFN, limited sample sizes, heterogeneous experimental designs/clinical conditions, the nature of IFN isoform, administration route, plus difficulties in assessing whether disease outcome was linked to type-I IFN or to the drugs used in combination. Key points which have emerged from these studies are: (i) IFN-β1b and IFN-β1a are the most potent subtypes for SARS-CoV inhibition (probably even more for SARS-CoV-2) \[[@bb0280],[@bb0520],[@bb0525]\]; (ii) type-I IFN must be administered as soon as possible after infection (ideally before symptom onset) although not in the late phase, because of possible tissue damage \[[@bb0025],[@bb0260],[@bb0530],[@bb0535]\]; and (iii) although IFN-α inhalation can lower SARS-CoV-2 infection rate and serve in prophylaxis or treatment (Chinese guidelines) \[[@bb0540]\], the preferred solutions remain the better-evaluated, safer intravenous and subcutaneous routes \[[@bb0470],[@bb0545]\].

Even though type-I IFN is being evaluated in several clinical trials, either alone (NCT04293887, NCT04320238, ChiCTR2000029989) or in combination (NCT04254874, NCT04276688, NCT04273763, NCT04315948, NCT04350684, NCT04350281, NCT04343768, NCT04350671), only one single retrospective study is currently available \[[@bb0550]\]. Zhou et al. compared 77 adults with laboratory-confirmed COVID-19 who were treated with either nebulized IFN-α2b (5 mU b.i.d.), oral umifenovir (200 mg t.i.d.), or a combination of both \[[@bb0550]\]. The authors found that treatment with IFN-α2b - with or without umifenovir - significantly reduced the duration of detectable virus in the upper respiratory tract and reduced the duration of elevated inflammatory markers (IL-6 and CRP). Unfortunately, this study has major flaws: (i) the study did not include a control group; (ii) only moderate forms of COVID-19 were included, with a median time from symptom onset to treatment of 11 days (range, 5 -22); (iii) patients in the IFN-α-treated group were significantly younger and had fewer comorbidities; (iv) the only patients treated with IFN-α2b alone were women; and (v) treatment regimens were quite heterogeneous since, in the combination group, 34% of patients received IFN-α2b as add-on to umifenovir and 52% started IFN-α2b after umifenovir had been stopped. None of the patients developed end organ dysfunction, nor respiratory failure requiring oxygen or critical care management. Interestingly, another study prospectively evaluated IFN-α1b nasal drops to prevent medical staff SARS-CoV-2 infection \[[@bb0555]\]. 2,944 medical staff members were allocated to either a low-risk group (n=2,415, 4-6 drops q.i.d. for 28 days) or a high-risk group (nasal drops + subcutaneous thymosin-α1 every week) depending on their exposure to the coronavirus. The control group consisted of medical staff in the same areas of Hubei Province, China. The 28-day incidence of COVID-19 amounted to zero for both groups, whereas over 2,000 new COVID-19 cases were diagnosed among medical personnel over the same period. Despite problems of major bias, this study suggests that IFN-α1b could serve as an efficient prophylactic against COVID-19.

Additional well-designed studies involving timely administration of IFN-α are thus eagerly awaited.

3.2. Interleukin-7 {#s0045}
------------------

Lymphopenia and lymphocyte exhaustion are hallmarks of COVID-19 and are possibly responsible for the cytokine storm due to defective clearance of both virus and infected cells. It is thus tempting to speculate that IL-7 - the major cytokine promoting lymphocyte expansion and possibly reversal of T cell exhaustion - may be useful in restoring immune system homeostasis. IL-7 exerts anti-apoptotic properties and induces potent proliferation of naive and memory T cells leading to replenishment of the circulating pool (CD4+ and CD8+) \[[@bb0560],[@bb0565]\]. IL-7 also increases T cell receptor repertoire diversity \[[@bb0570]\] and promote the expression of cell adhesion molecules, improving the capacity of T cells to traffic to infection sites \[[@bb0575]\]. More importantly, the administration of recombinant IL-7 (rIL-7) does not induce hyperinflammatory response through stimulating adaptive immunity. Indeed, rIL-7 has been successfully used to treat T cell exhaustion following septic shock and restore CD4+ T cells in HIV patients, with no evidence of clinical deterioration nor proinflammatory marker exacerbation (TNF-α, IL-6, CRP) \[[@bb0580],[@bb0585]\]. Surprisingly, at the time of writing this review, there is no trial registered yet to evaluate this strategy. If such a study were to be launched, the perfect timing for lymphocyte restoration would need to be strictly determined.

4. Anti-cytokine interventions {#s0050}
==============================

4.1. Interleukin-6 inhibition {#s0055}
-----------------------------

Not only is IL-6 a major mediator within the cytokine storm, its levels have been closely correlated with ARDS severity and outcome, along with blood SARS-CoV-2 viral load \[[@bb0355],[@bb0370],[@bb0590]\]. A recent meta-analysis reported 2.9-fold higher serum levels in patients with complicated COVID-19 compared to patients with non-complicated disease \[[@bb0595]\]. Inhibitors of IL-6 or its receptor have been successful in treating other cytokine storm syndromes, such as reHLH associated with adult-onset Still's disease \[[@bb0600]\], or CRS secondary to CAR T cell therapies \[[@bb0140],[@bb0605]\]. Several drugs are available, including IL-6 receptor inhibitors (tocilizumab, sarilumab) and IL-6 inhibitors (siltuximab, clazakizumab, sirukumab) \[[@bb0610]\].

To date, only four studies and case reports are available \[[@bb0615], [@bb0620], [@bb0625], [@bb0630], [@bb0635]\].

Xu et al. have reported on 21 severe or critical patients treated with tocilizumab although there was no control group \[[@bb0615]\]. This first study demonstrated decreased oxygen requirements (75%), resolution of CT-scan abnormalities (90.5%), and clinical improvement (100%). No adverse events or deaths were reported. To estimate the results of a potential control group not administered tocilizumab, Xu *et al.* referred to the results of a previous study which found a baseline mortality rate of 60% in critical patients and 11% in severe patients admitted to one ICU \[[@bb0045]\].

The second study, from China, retrospectively analyzed 15 patients (median age, 73 years) with moderate (n=2), severe (n=6), and critical (n=7) forms of COVID-19 \[[@bb0620]\]. Eight patients received concurrent methylprednisolone. Three patients died (all from the critical group), 1 patient improved, 9 were clinically stabilized and 2 experienced disease worsening. A persistent increase of serum IL-6 was observed in 4 (out of 5) patients resulting in either aggravation or fatal outcome.

The third study, performed in Italy, analyzed 21 patients with COVID-19 who developed ARDS and were enrolled into a compassionate-use program \[[@bb0625]\]. All patients received siltuximab at doses ranging from 700 to 1,200 mg. Clinical improvement was observed in 33% of patients, 43% stabilized as evidenced by absence of clinically-relevant change in condition, and 24% experienced a worsened condition. One patient died, and one patient suffered a cerebrovascular event. The absence of control group precludes final conclusions, basically because the mortality rate for patients undergoing standard of care was not mentioned.

Finally, Roumier et al. reported their experience regarding tocilizumab in 30 selected patients (23% in ICU) \[[@bb0635]\]. Patients were aged \<80, with \>5-days disease duration, and with severe pneumonia (i.e. requiring \> 6L/min of oxygen) and rapidly deteriorating (i.e. increase by more than 3L/min of oxygen flow within the previous 12 hours). The control group (standard of care) included patients matched for age, gender, and disease severity. Patients were followed-up for a median of 8 days. Tocilizumab significantly reduced mechanical ventilation requirement (OR: 0.42; p=0.025) and risk of subsequent ICU admission (OR: 0.17; p=0.001). There was a trend, though no statistical difference, toward lower mortality. Tocilizumab was well-tolerated, yet the author reported two mild liver test disturbances, and one ventilator-acquired pneumonia.

These mixed results must be further clarified. Most notably, since experimental models have shown that IL-6 can either suppress or facilitate viral replication \[[@bb0640]\], one crucial remaining question to answer will be the optimal timing for anti-IL6 administration. If too early, the drugs may adversely affect viral clearance. If too late, the drugs may not be effective enough. The perfect timing of this must be assessed in trials. At present, several clinical trials are under way to evaluate the safety and efficacy of IL-6 inhibitors, with various protocols and comparators ([clinicaltrials.gov](http://clinicaltrials.gov){#ir0005} identifiers: NCT04332913, NCT04322773, NCT04317092, NCT04320615, NCT04306705, NCT04324073, NCT04315298, NCT04315480, NCT04321993, NCT04335071, NCT04348500, NCT04329650, NCT04330638, NCT04345289, NCT04327388, NCT04341870). In China, tocilizumab is also being evaluated either alone or in combination (identifiers: ChiCTR2000029765, ChiCTR2000030796, ChiCTR2000030442, ChiCTR2000030894).

It is noteworthy that since March 2020 tocilizumab has been formally included in the National Health Commission of China\'s COVID-19 diagnosis and treatment program (7^th^ edition): "Tocilizumab can be used in patients with extensive bilateral lung lesions opacity or in severe or critical patients, who have elevated laboratory detected IL-6 levels". More recently, the Infectious Diseases Society of America (IDSA) has published guidelines and recommends that, for patients who have been admitted to the hospital with COVID-19, tocilizumab should be used only in the context of a clinical trial, due to "knowledge gap" \[[@bb0645]\].

4.2. Interleukin-1 family: IL-1 and IL-18 blockade {#s0060}
--------------------------------------------------

IL-1β and its natural antagonist (i.e. IL-1Ra) have been observed in the peripheral blood and BALF of patients with COVID-19-induced pneumonia \[[@bb0110],[@bb0115],[@bb0130],[@bb0355]\]. This is a striking result since IL-1β has a short half-life in serum and is rarely isolated in peripheral blood. This finding suggests high levels of IL-1β production, reinforced by reports indicating *IL1B* and *IL1R1* gene upregulations \[[@bb0285]\].

IL-1β is a proinflammatory cytokine that is activated and secreted upon activation of the inflammasome \[[@bb0160]\]. NLRP3, the most-frequently studied inflammasome, is activated by danger signals, which have been suggested to be viroporin A, E protein, or ORF3 proteins from SARS-CoV and MERS-CoV \[[@bb0190],[@bb0200],[@bb0650]\]. Pyroptosis has also been associated with coronavirus infection \[[@bb0080],[@bb0655]\]. Elevated IL-1β is central to ARDS \[[@bb0660]\] and HLH \[[@bb0445],[@bb0665]\]. Indeed, HLH is a well-known and frequent complication in about 10% of juvenile and adult-onset Still's disease, whith pathophysiology marked by very high levels of IL-1β \[[@bb0405],[@bb0670]\]. Anakinra, a recombinant IL-1Ra, has proved effective in treating HLH (via continuous intravenous infusion) \[[@bb0675],[@bb0680]\], and it is currently used in IL-1-induced autoinflammatory diseases, including cryopyrinopathies (dominant NLRP3 gain-of-function) \[[@bb0685]\], familial Mediterranean fever (pyrin inflammasome deregulation) \[[@bb0690]\], PFAPA \[[@bb0695]\], and Still's disease \[[@bb0700]\]. In a reanalysis of data from a phase-III randomized trial, anakinra was associated with significant survival improvement in patients with severe sepsis and features of reHLH, without triggering any serious adverse events \[[@bb0705]\]. Today, anakinra is being evaluated in this context in the PROVIDE study (NCT03332225). Often efficacious within hours, anakinra has a short half-life and is considered safe. It may thus constitute a drug of choice for certain selected COVID-19 patients presenting signs of imminent cytokine storm. So far, no clinical data are available but clinical trials are ongoing to test anakinra in COVID-19 (NCT04330638, NCT04341584, NCT04339712, NCT04324021).

Canakinumab, a monoclonal antibody targeting IL-1β, is also being investigated in a single-arm observational study (NCT04348448); however its longer half-life (26 days) may be problematic for infected patients.

IL-18 is mainly produced by macrophages as an inactive precursor which is processed by inflammasome-activated caspase-1, like IL-1β \[[@bb0160],[@bb0710]\]. By binding to IL-18R, IL-18 (in combination with IL-12/-15) acts on CD4+, CD8+ T cells, and NK cells to induce IFN-γ, the major driver of macrophage activation syndrome (i.e. HLH) \[[@bb0425],[@bb0430],[@bb0445],[@bb0715]\]. IL-18 is one of the upregulated cytokines in sera and BALF from COVID-19 patients \[[@bb0130],[@bb0720]\]. In addition, IL-18 has been reported as a biomarker of Still's disease, its levels being correlated with disease activity \[[@bb0725]\]. High levels of serum IL-18 have also been reported in patients with a newly-described autoinflammatory disease associating pulmonary alveolar proteinosis and recurrent macrophage activation syndrome (IL18PAP-MAS) \[[@bb0730]\]. Tadekinig alfa is a recombinant IL-18 binding protein (IL-18BP, a naturally-occurring inhibitor of IL-18) which has shown encouraging results in Still's disease \[[@bb0675],[@bb0680]\]. Interestingly, rIL-18BP was uused to successfully treat a 6-week old girl with life-threatening NLRC4-associated hyperinflammation (HLH), which was refractory to corticosteroids, IL-1 blockade, anti-TNF, cyclosporine, and vedolizumab \[[@bb0735]\]. Although blocking IL-18 could be of interest in COVID-19, there is no clinical evidence, nor any registered RCT assessing the safety and efficacy of rIL-18BP in this framework.

4.3. Interferon-γ inhibition {#s0065}
----------------------------

Intriguingly, while being central to cytokine storm occurrence in SARS-CoV infection \[[@bb0740]\], IFN-γ was not found to be elevated in the sera or BALFs of patients with severe forms of COVID-19 \[[@bb0110],[@bb0115],[@bb0130],[@bb0745]\]. Actually, there are even conflicting results showing a mild elevation in the sera of non-severe patients \[[@bb0115],[@bb0130],[@bb0375],[@bb0750]\]. However, one meta-analysis has shown a link between high IL-6/IFN-γ ratio and disease severity, thereby indicating that lower levels of IFN-γ should rather predict poorer outcomes \[[@bb0755]\]. Emapalumab, a monoclonal antibody directed against IFN-γ is approved for treating pediatric and adult primary HLH patients with refractory, recurrent, or progressive disease or intolerance to conventional therapy (despite a lack of clinical trial data in adults) \[[@bb0760],[@bb0765]\]. However, in the single RCT on 34 patients, serious adverse reactions occurred in 53% of the recipients, including (bacterial, viral, and opportunistic) infections and multiple organ dysfunction syndrome. In addition, data from mouse models suggest that simultaneously inhibiting multiple cytokine-signaling pathways (such as with JAK inhibitors) may be more effective than targeting IFN-γ alone \[[@bb0770],[@bb0775]\]. RCTs are now ongoing to evaluate emapalumab in HLH (either primary or reactive: NCT01818492, NCT0331275, NCT03985423, NCT03311854) and in COVID-19 (NCT04324021).

4.4. Tumor necrosis factor-α inhibition {#s0070}
---------------------------------------

TNF is present in COVID-19 patients' blood and diseased tissues and its levels are even higher in patients with severe disease \[[@bb0115],[@bb0305],[@bb0375],[@bb0780]\]. Since TNF inhibitors are readily available and well-evaluated drugs, some authors postulate that there is sufficient evidence to conduct clinical trials in COVID-19 \[[@bb0785]\]. Nevertheless, the literature remains very scanty when exploring possible treatments for cytokine storm or HLH. Indeed, while a few case reports described the benefits of etanercept \[[@bb0790], [@bb0795], [@bb0800]\], other studies have shown that it may trigger or worsen disease progression \[[@bb0805], [@bb0810], [@bb0815]\]. However, some cases argue for TNF inhibitors use in COVID-19: (i) TNF neutralization provides protection against SARS-CoV infection in animal models \[[@bb0820]\]; (ii) anti-TNF induce a rapid decrease of IL-6 and IL-1 concentrations in patients with active rheumatoid arthritis \[[@bb0825]\]; (iii) anti-TNF trigger a reduction of adhesion molecules and vascular endothelial growth factor, which is partly responsible for capillary leak \[[@bb0830],[@bb0835]\]; and (iv) anti-TNF lead to less leucocyte traffick to inflamed tissues due to reduced adhesion molecules and chemokines with subsequent reduction of cell content and exudate \[[@bb0840]\]. It is suggested that initial assessments of TNF inhibitors should be done in patients with moderate disease, as soon as possible after their admission to hospital \[[@bb0785]\]. To date, only a single RCT evaluating adalimumab in COVID-19 has been registered (ChiCTR2000030089).

4.5. Non-targeted therapies {#s0075}
---------------------------

### 4.5.1. Corticosteroids {#s0080}

Corticosteroids are potent cytokine inhibitors working through several mechanisms but mainly by inhibiting the NF-κB transcription factor. They are the cornerstone of treatments for cytokine storms and HLH associated with autoimmune/autoinflammatory diseases. However, their use in managing SARS-CoV-2 patients is currently highly contested \[[@bb0845], [@bb0850], [@bb0855]\]. Indeed, a systematic review of observational studies on corticosteroids administered to SARS-CoV infected patients reported no survival benefit, plus potential harm (although mostly inconclusive) \[[@bb0475]\]. Similarly, a systematic review of observational studies in influenza found a higher risk of mortality and secondary infections with (high-dose) corticosteroids \[[@bb0860]\]. Further, a study of patients given corticosteroids for MERS-CoV infection revealed delayed clearance of the virus and zero effect of corticosteroids on mortality \[[@bb0865]\]. Finally, while most previous guidelines did not recommend corticosteroid use for treating sepsis in the absence of refractory shock, a recent statement (triggered by the analysis of two RCTs) made a weak recommendation to use corticosteroids in sepsis patients \[[@bb0870]\]. Altogether, it has become apparent that corticosteroids may be more detrimental than beneficial in COVID-19 and the WHO (as well as IDSA) recommends that they not be used outside of clinical trials \[[@bb0875]\]. However, given that these data are derived from previous infections, corticosteroids have been recommended as adjuvant therapy by China\'s National Health Commission. In particular, one study of 201 patients has found that, among patients who developed ARDS (n=84, 41.8%), treatment with methylprednisolone decreased the risk of death (HR, 0.38; 95% CI, 0.20-0.72, p=0.003) \[[@bb0120]\]. Nevertheless, in a recent meta-analysis of 15 studies on COVID-19, corticosteroids were associated with significantly higher mortality (RR=2.11, p=0.019), longer length-of-stay (P\<0.001), and higher rates of bacterial infection (RR=2.08, P\<0.001) \[[@bb0880]\].

Such conflicting findings are most likely linked to the heterogeneity of protocols and clinical conditions and, above all, to different timings of in corticosteroid administration. Thus, there is no doubt that the main challenge of up-coming RCTs will be to define the precise moment and best dosages for preventing hyperinflammation, while lessening the risks of prolonged viral shedding and secondary bacterial infections.

### 4.5.2. Chloroquine and hydroxychloroquine {#s0085}

There has been tremendous debate about chloroquine or its derivative, hydroxychloroquine, as potentially effective treatments in COVID-19. Although these drugs have *in vitro* antiviral properties \[[@bb0885], [@bb0890], [@bb0895]\], including on SARS-CoV-2 \[[@bb0900]\], studies have systematically failed to demonstrate positive effects in human viral diseases. Both drugs can prevent the virus' binding to hACE2 *in vitro*, or inhibit viral cycle \[[@bb0905]\]. In addition, they are used in autoimmune and inflammatory diseases (mainly systemic lupus erythematosus) for their immunomodulating properties. It is hypothesized that their action is tied to their ability to accumulate in lysosomes where they raise pH and interfere with antigen degradation and presentation to CD4+ T cells \[[@bb0910],[@bb0915]\]. Data also indicate that they reduce proinflammatory IL-6, IL-18, and TNF-α \[[@bb0920],[@bb0925]\]. Lastly, they inhibit endosomal TLRs and have anti-inflammatory effects, such inhibiting prostaglandin synthesis or lipid peroxidation \[[@bb0930], [@bb0935], [@bb0940]\].

Altogether, chloroquine and hydroxychloroquine are thought to be able to reduce viral load and prevent cytokine storm. At the time of writing this review, seven articles are reporting clinical data (observational studies or clinical trials), with either positive (n=4) \[[@bb0945], [@bb0950], [@bb0955], [@bb0960]\] or negative (n=5) results \[[@bb0965], [@bb0970], [@bb0975], [@bb0980]\], but no definitive conclusions can currently be drawn because of major biases in all of the studies \[[@bb0985]\]. Several RCTs are also ongoing to evaluate these drugs in the context of COVID-19 (n=32 registered with [www.clinicaltrials.gov](http://www.clinicaltrials.gov){#ir0010}; n=16 with the Chinese clinical trial registry).

In conclusion, it is noteworthy that several national guidelines already include chloroquine or hydroxychloroquine whereas the IDSA recommends reserving its use (in combination with azithromycin or not) for clinical trials.

### 4.5.3. JAK inhibitors and colchicine {#s0090}

Other drugs are currently being investigated, such as the JAK inhibitors (i.e. tofacitinib, NCT04332042; baricitinib, NCT04321993, NCT04345289, NCT04320277, NCT04346147, NCT04340232; ruxolitinib, NCT04348695, NCT04331665, NCT04337359, NCT04338958, NCT04334044, NCT04348071) or colchicine. The JAK/STAT pathway lies downstream of several cytokines which are increased in HLH and thus it is an attractive target to abrogate the signaling of multiple cytokine pathways \[[@bb0990]\]. However, caution should be applied in using JAK inhibitors because: (i) COVID-19 can be complicated by coagulopathy with increased frequency of thromboembolic events, and the FDA has recently warned clinicians about increased thromboembolism risk with some JAK inhibitors \[[@bb0995]\]; ii) treatment with JAK inhibitors is associated with increased frequency of herpes zoster virus reactivation; and (iii) pan-JAK inhibitors may repress some cytokines required for antiviral defense (type-I IFN) or for immune restoration (IL-2, IL-7) \[[@bb1000],[@bb1005]\].

Colchicine is a long-established drug with anti-inflammatory properties used to treat patients with Behçet's disease or familial Mediterranean fever. Colchicine inhibits IL-1β and its subsequent inflammatory cascade principally by blocking pyrin and (to a lesser extent) NLRP3 inflammasome activation. Until now, there has been no data indicating that pyrin is activated upon SARS-CoV-2 infection and this would appear rather unlikely. On the other hand, NLRP3 is likely to be activated following virus entry into the cell \[[@bb0190], [@bb0195], [@bb0200],[@bb0325],[@bb0650]\]. Nevertheless, the inhibition of NLRP3 inflammasome by colchicine has not been firmly demonstrated since *in vitro* it does not prevent IL-1β secretion induced by typical NLRP3 stimuli (i.e. ATP, nigericin) \[[@bb1010]\]. Five RCTs are currently under way to test the efficacy of colchicine in COVID-19 patients (NCT04322682, NCT04322565, NCT04328480, NCT04326790, NCT04350320).

5. Conclusion {#s0095}
=============

The rapid diffusion of COVID-19 drives an urgent search for effective treatments, mainly for its severe forms. The disease is polyphasic in nature, with secondary cytokine storm and ARDS resulting in poor outcomes, plus overwhelmed intensive care units and hospitals. In the very early stages of the disease, treatment should focus on reducing viral load either by specific antivirals or by stimulating type-I IFN. Later on, in selected patients, therapies targeting proinflammatory cytokines could suppress hyperinflammation, while some cytokines (IL-7) could theoretically trigger immune restoration. In clinical practice, unfortunately, patients are unlikely to be detected early enough (i.e. before/at symptom onset) to benefit from antiviral strategies. Therefore, factors to predict progression toward severe forms of the disease are, at present, the most urgently needed and awaited determinants. A highly-structured approach, which includes immune monitoring, would thus be of utmost importance.
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